Trial Profile
A Phase III Open-Label, Single Group Extension Study of the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Idebenone (Primary)
- Indications Friedreich's ataxia
- Focus Therapeutic Use
- Acronyms IONIA-E
- Sponsors Santhera Pharmaceuticals
- 20 Nov 2014 New trial record
- 11 Jul 2011 The primary endpoint has been changed from hematology, nature and frequency of AEs, blood and urine chemistry, physical/neurological examination and vital signs, electrocardiograms to change in ICARS, according to ClinicalTrials.gov (NCT00697073).
- 20 Aug 2010 The study was changed from recruiting to completed.